GlassScriptPhysician profile
James S Prine
NPI 1639190036
$2,309.90
in general payments reported to CMS, 2019-2025
18 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $453 · 2021: $100 · 2022: $401 · 2023: $329 · 2024: $170 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.48 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.13 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $360.12 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.10 | 2019-2024 | Jardiance |
| Becton, Dickinson and Company | $216.67 | 2020 | |
| Stryker Corporation | $178.59 | 2025 | Blueprint Patient Specific Instrumentation |
| Glaxosmithkline, LLC. | $160.89 | 2020-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $140.16 | 2019 | |
| Medtronic, INC. | $115.26 | 2023-2024 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $84.99 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $65.67 | 2021-2022 | |
| Lilly USA, LLC | $63.39 | 2020-2022 | |
| Allergan, INC. | $56.50 | 2019 | |
| Amarin Pharma, INC. | $41.55 | 2020 | |
| Merck Sharp & Dohme LLC | $34.84 | 2019-2020 | |
| Exact Sciences Corporation | $26.76 | 2023 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.57 | 2019 | |
| Abbott Laboratories | $20.54 | 2024 | Eterna |
| Amgen INC. | $14.17 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Prine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.